A share price of Cogent Biosciences Inc [COGT] is currently trading at $33.42, up 2.96%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The COGT shares have gain 136.52% over the last week, with a monthly amount glided 106.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on November 10, 2025, when Wedbush upgraded its rating to a Outperform but kept the price target unchanged to $38 for it. Previously, Stifel upgraded its rating to Buy on November 10, 2025, and kept the price target unchanged to $40. On October 16, 2025, Stifel initiated with a Hold rating and assigned a price target of $16 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $30 on September 03, 2025. Scotiabank initiated its recommendation with a Sector Outperform and recommended $17 as its price target on March 07, 2025. Needham downgraded its rating to Hold for this stock on December 11, 2024. In a note dated February 26, 2024, Robert W. Baird downgraded a Neutral rating on this stock and revised its target price from $14 to $8.
Cogent Biosciences Inc experienced fluctuations in its stock price throughout the past year between $3.72 and $36.15. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $33.42 at the most recent close of the market. An investor can expect a potential return of 18.19% based on the average COGT price forecast.
Analyzing the COGT fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -69.82%, Pretax Profit Margin comes in at -66.19%, and Net Profit Margin reading is -66.19%. To continue investigating profitability, this company’s Return on Assets is posted at -1.03, Equity is -1.2 and Total Capital is -1.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.03 points at the first support level, and at 26.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.66, and for the 2nd resistance point, it is at 37.89.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cogent Biosciences Inc [NASDAQ:COGT] is 6.38. Further, the Quick Ratio stands at 6.38, while the Cash Ratio is 2.18.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jul 10 ’25 when 2.78 million shares were purchased. Chief Commercial Officer, Pinnow Cole completed a deal on Jan 14 ’25 to buy 43750.0 shares.
